P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry
| العنوان: | P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry |
|---|---|
| المؤلفون: | James W. Hardin, K. Toomey, Cristina Gasparetto, Prashant Joshi, Mohit Narang, Rafat Abonour, Devender Dhanda, H.R. Terebelo, Sikander Ailawadhi, Mia He, Lynne I. Wagner, Robert M. Rifkin, Hans C. Lee, Brian G.M. Durie, Amit Agarwal, Julia Braverman, Sundar Jagannath |
| المصدر: | Clinical Lymphoma Myeloma and Leukemia. 21:S109 |
| بيانات النشر: | Elsevier BV, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Health related quality of life, Cancer Research, medicine.medical_specialty, business.industry, Context (language use), Small sample, Hematology, medicine.disease, Clinical trial, Oncology, Internal medicine, Relapsed refractory, medicine, Trial Eligibility Criteria, business, Multiple myeloma, Cohort study |
| الوصف: | Background For pts with MM, HRQL is a key determinant of treatment choice in late-line therapies such as ide-cel, a BCMA-directed CAR T cell therapy. In KarMMa (NCT03361748), 54.2% of pts showed clinically meaningful improved HRQL from baseline to quarter (Q) 3, as measured by EQ-5D-5L; 8.5% experienced deterioration (Blood. 2020;136 [Suppl]:28–29). Analysis of HRQL in pts who received alternate, non-CAR T cell therapies could contextualize the impact of ide-cel on HRQL. The Connect® MM Registry (NCT01081028) is a large, US, multicenter, prospective observational cohort study of largely community-based pts with newly diagnosed MM (NDMM) at study entry. It was used for a descriptive analysis assessing HRQL outcomes in triple-class exposed real-world pts who met KarMMa trial eligibility criteria but received alternate therapies. Method From 2009-2016, the Registry enrolled 3011 pts with symptomatic NDMM diagnosed ≤2 months prior to study entry at 250 community, academic, and government sites across the US. Pts agreed to complete HRQL forms at study enrollment and every Q of follow-up. Pts with RRMM included in this analysis met KarMMa eligibility criteria. HRQL was measured from the time of KarMMa eligibility (D1) using EQ-5D-3L and FACT-MM total score instruments. Results As of data cutoff (7 Feb 2020), 32 pts with RRMM from the Registry met KarMMa eligibility criteria. Median age was 64.1 y (range, 45.5–88.8). Median time to D1 since initial diagnosis was 3.4 y (range, 1.6–5.5); 24 pts (75%) had prior stem cell transplant; median prior lines of therapy was 7.5. At D1, pts initiated regimens that included IMiDs (n=20), proteasome inhibitors (n=15) and anti-CD38 monoclonal antibodies (n=7). HRQL form completion rate at Q3 was 64.7%. The baseline index score was 0.73 for Registry pts. Median EQ-5D-3L score (range) at D1 (n=21) was 0.761 (0.263–1) and 0.708 (0.263–1) at Q3 (n=11). At D1, 30% of pts experienced clinically meaningful improvement in EQ-5D-3L from baseline; 35% each experienced no change or deterioration in HRQL. By Q3, 20%, 30%, and 50% of pts experienced improvement from baseline, no change, and deterioration in HRQL, respectively. By Q3 post treatment initiation, a substantial proportion of ide-cel–eligible real-world pts with RRMM from the Connect MM Registry who received various alternate (non-CAR T cell) MM regimens experienced meaningful deterioration of HRQL (measured by EQ-5D-3L) from D1 over time. Conclusion In the context of the KarMMa trial, it was observed that a higher proportion of pts on ide-cel experienced meaningful improvement in HRQL (measured by EQ-5D-5L) and fewer pts experienced deterioration by Q3 after treatment. Limitations of this analysis may include small sample size and use of different versions of EQ-5D assessments. HRQL remains an important goal of MM treatment, and therapies that improve HRQL should be developed explicitly. These results support the need for replication in a larger pt sample and complement clinical trial findings. |
| تدمد: | 2152-2650 0336-1748 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::563d1719ee774586d2740db6a778a5db https://doi.org/10.1016/s2152-2650(21)02263-1 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........563d1719ee774586d2740db6a778a5db |
| قاعدة البيانات: | OpenAIRE |
Full Text via ClinicalKey | تدمد: | 21522650 03361748 |
|---|